Population pharmacokinetics of esketamine nasal spray and its metabolite noresketamine in healthy subjects and patients with treatment-resistant depression

C Perez-Ruixo, S Rossenu, P Zannikos, P Nandy… - Clinical …, 2021 - Springer
Background Esketamine nasal spray is approved for treatment-resistant depression.
Objective The objective of this study was to characterize the pharmacokinetics of esketamine …

[HTML][HTML] Intranasal esketamine (SpravatoTM) for use in treatment-resistant depression in conjunction with an oral antidepressant

R Bahr, A Lopez, JA Rey - Pharmacy and Therapeutics, 2019 - ncbi.nlm.nih.gov
Major depressive disorder (MDD) affects more than 16 million adults each year in the United
States. 1 The incomplete response that many persons experience with current …

Esketamine for treatment resistant depression: a trick of smoke and mirrors?

C Gastaldon, D Papola, G Ostuzzi… - … and Psychiatric Sciences, 2020 - cambridge.org
In March 2019, the US Food and Drug Administration (FDA) approved a nasal spray
formulation of esketamine for the treatment of resistant depression in adults. Esketamine is …

[HTML][HTML] Predicting outcome with Intranasal Esketamine treatment: A machine-learning, three-month study in Treatment-Resistant Depression (ESK-LEARNING)

M Pettorruso, R Guidotti, G d'Andrea, L De Risio… - Psychiatry …, 2023 - Elsevier
Abstract Treatment-resistant depression (TRD) represents a severe clinical condition with
high social and economic costs. Esketamine Nasal Spray (ESK-NS) has recently been …

A word to the wise about intranasal esketamine

AF Schatzberg - American Journal of Psychiatry, 2019 - Am Psychiatric Assoc
Rarely has there been so much anticipation for a new antidepressant as has been seen for
intranasal esketamine, the putatively more effective enantiomer of ketamine. This reflects the …

[HTML][HTML] Ketamine for the treatment of major depression: a systematic review and meta-analysis

S Nikolin, A Rodgers, A Schwaab, A Bahji… - …, 2023 - thelancet.com
Background Intranasal esketamine has received regulatory approvals for the treatment of
depression. Recently a large trial of repeated dose racemic ketamine also demonstrated …